| ln Vitro |
Disodium 8-Br-ADPR (100 μM; pre-incubated before glucagon treatment) specifically blocked glucagon-induced persistent nuclear calcium signaling in mouse primary hepatocytes without altering cytoplasmic calcium signaling [1]. Disodium 8-Br-ADPR (100 μM; pre-incubated for 30 min before ADPR treatment) completely blocked the ADPR-induced calcium ion flow between the perinuclear space and nucleoplasm in the isolated nucleus of mouse primary hepatocytes [1]. Disodium 8-Br-ADPR (100 μM; pre-incubated for 30 min before 4 hours of 100 nM glucagon treatment) significantly reduced glucagon-induced G6pc and Pck1 mRNA expression in mouse primary hepatocytes [1]. Disodium 8-Br-ADPR (100 μM; 20 min) inhibited B16F10-induced translocation of perforin and granzyme B to mouse NK cell immune synapses [2]. Disodium 8-Br-ADPR (100 μM; 20 min) can reduce the cytotoxic activity of mouse NK cells against B16F10 melanoma target cells [2].
|
|---|---|
| ln Vivo |
Disodium 8-Br-ADPR (32 mg/kg; intravenous injection; single dose) can reduce fasting blood glucose and pyruvate-induced blood glucose levels in wild-type mice by inhibiting hepatic gluconeogenesis gene expression and CRE-mediated transcriptional activity [1]. Disodium 8-Br-ADPR (32 mg/kg; intravenous injection; single dose) can reduce pyruvate-induced blood glucose levels in diabetic db/db mice by inhibiting hepatic gluconeogenesis gene expression and CRE-mediated transcriptional activity [1].
|
| Cell Assay |
Immunofluorescence [2]
Cell Types: Mouse natural killer (NK) cells Tested Concentrations: 100 μM Incubation Duration: 20 minutes (pre-incubation) Experimental Results: Blocked the translocation of B16F10-induced perforin and granzyme B to the immune synapse between NK cells and B16F10 cells. Western Blot Analysis [2] Cell Types: Mouse natural killer (NK) cells Tested Concentrations: 100 μM Incubation Duration: 20 minutes (pre-incubation) Experimental Results: Inhibited PME-induced translocation of perforin and granzyme B from intracellular granules to membrane-rich components. ELISA detection [2] Cell Types: Mouse natural killer (NK) cells Tested Concentrations: 100 μM Incubation Duration: 20 minutes (pre-incubation) Experimental Results: Inhibited B16F10-induced NK cell granzyme B secretion, reducing the amount of granzyme B released into the culture medium. |
| Animal Protocol |
Animal/Disease Models:Physiologically fasted C57BL/6J mice (male, 8-12 weeks old) [1]
Doses: 32 mg/kg Route of Administration: Intravenous injection; single dose Experimental Results: Reduced hepatic CRE luciferase activity. Hepatic G6pc and Pck1 mRNA levels decreased by approximately 50%. In the pyruvate tolerance test, blood glucose levels decreased by approximately 30-40% within 0-90 minutes after pyruvate injection. Animal/Disease Models:Diabetic B6.BKS(D)-Leprdb/J mice (db/db) (male, 8-12 weeks old) [1] Doses: 32 mg/kg< Route of Administration: Intravenous injection; single dose Experimental Results: Hepatic CRE luciferase activity was reduced. Hepatic G6pc mRNA levels decreased by approximately 40%, and Pck1 mRNA levels decreased by approximately 30%. At all time points, blood glucose levels in the pyruvate tolerance test decreased by approximately 60-70%. |
| References |
|
| Appearance |
Solid
|
|---|---|
| Synonyms |
8-Bromoadenosine-5'-O-diphosphoribose disodium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: 请将本产品存放在密封保护的环境中，避免受潮。 |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
